Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Systems analysis identifies potential target genes to overcome cetuximab resistance in colorectal cancer cells

5 Feb 2019

Abstract excerpt

Cetuximab (CTX), a monoclonal antibody against epidermal growth factor receptor, is being widely used for colorectal cancer (CRC) with wild-type (WT) KRAS. However, its responsiveness is still very limited and WT KRAS is not enough to indicate such responsiveness. Here, by analyzing the gene expression data of CRC patients treated with CTX monotherapy, we have identified DUSP4, ETV5, GNB5, NT5E, and PHLDA1 as...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Colorectal Cancer Treatments and Studies
Share to Genetic factors in colorectal cancer

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30719834
DOI: 10.1111/febs.14773

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Systems analysis identifies potential target genes to overcome cetuximab resistance in colorectal cancer cellsPMID 30719834Read ↗

Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab.Semantic proximity Read ↗

Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab.Semantic proximity Read ↗

Systems Biology Approach to Gene Network Analysis Identifies Therapeutic and Diagnostic Targets in Colorectal CancerSemantic proximity Read ↗

Cetuximab inhibits colorectal cancer development through inactivating the Wnt/β-catenin pathway and modulating PLCB3 expressionSemantic proximity Read ↗

Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).Semantic proximity Read ↗

Pathway activation strength is a novel independent prognostic biomarker for cetuximab sensitivity in colorectal cancer patientsSemantic proximity Read ↗

ETV5 expression positively correlates with promoter methylation and predicts response for 5-FU-based adjuvant therapy response in proximal colon cancerSemantic proximity Read ↗

miR-100-5p Enhanced Cell Cycle-mediated Chemoresistance Through Modulating CTDSPL/pRB/E2F1 Signaling Pathway in Oxaliplatin-Resistant Colorectal CancerSemantic proximity Read ↗

Model-based analysis of response and resistance factors of cetuximab treatment in gastric cancer cell linesSemantic proximity Read ↗

The feedback loop of EFTUD2/c-MYC impedes chemotherapeutic efficacy by enhancing EFTUD2 transcription and stabilizing c-MYC protein in colorectal cancerSemantic proximity Read ↗

Identification of AKT1/β-catenin mutations conferring cetuximab and chemotherapeutic drug resistance in colorectal cancer treatmentSemantic proximity Read ↗

KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.